Sofinnova Partners, a European life sciences venture capital firm based in Paris, London, and Milan, has launched a new investment strategy focused on digital medicine, which will be led by partners Edward Kliphuis and Simon Turner.
Sofinnova Partners (Sofinnova), a European life sciences venture capital firm based in Paris, London, and Milan, has launched a new investment strategy focused on digital medicine, which will be led by partners Edward Kliphuis and Simon Turner.
The duo have over a decade of experience investing in startups at the intersection of biology, data, and computation.
According to a company statement, Sofinnova Digital Medicine will back entrepreneurs at the “cutting edge of technology and biology and help them scale to become global leaders. Like all the funds on Sofinnova’s platform, Sofinnova Digital Medicine will focus on developing innovations that address systemic challenges in healthcare and have the potential to profoundly improve the lives of patients worldwide”.
The launch of Sofinnova Digital Medicine marks the firm’s sixth and newest strategy in its multi-fund platform which spans the life sciences sector, from seed to later-stage investments in the most promising and disruptive technologies.
